Hold Dr Reddys Laboratories: Ventura Securities

Ventura Securities has recommended hold rating on Dr Reddy Laboratories (DRL), in its February 21, 2013 research report. The research firm, expects company's performance in FY14 to remain muted and restricted to single digit growth.
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead Realasset
moneycontrol.com

Home » News » Recommendations

Feb 25, 2013, 12.22 PM | Source: Moneycontrol.com

Hold Dr Reddys Laboratories: Ventura Securities

Ventura Securities has recommended hold rating on Dr Reddy Laboratories (DRL), in its February 21, 2013 research report. The research firm, expects company's performance in FY14 to remain muted and restricted to single digit growth.

Like this story, share it with millions of investors on M3

Hold Dr Reddys Laboratories: Ventura Securities

Ventura Securities has recommended hold rating on Dr Reddy Laboratories (DRL), in its February 21, 2013 research report. The research firm, expects company's performance in FY14 to remain muted and restricted to single digit growth.

Post Your Comments

Share Cancel

(more)

, Ventura |

Ventura Securities has recommended hold rating on Dr Reddy Laboratories (DRL), in its February 21, 2013 research report. The research firm, expects company's performance in FY14 to remain muted and restricted to single digit growth.

"Dr Reddy Laboratories revenue grew 3.5% yoy to Rs 2865 crore. However, excl. olanzapine exclusivity in Q3FY13, revenue grew 23% yoy. The reported EBITDA margin came in at 20.5%, lower than the street expectation mainly on account of a decline in the PSAI (pharma services and active ingredients) gross margin and higher R&D spend of 7%, vs 5.5% yoy. Due to lower revenue growth and the decline in the EBITDA margin, adjusted PAT declined 29.2% yoy to Rs 363.3 crore.

Domestic formulations grew 11.7% yoy, led by strong growth in biosimilars and the launch of brands. Biosimilars portfolio witnessed a strong growth of 47% YoY albeit on a smaller base. However, the domestic formulations growth has been lower than the Industry, the direction is positive and the management would be implementing plans to drive performance.

Revenue (excl. Olanzapine exclusivity) growth of 23% yoy was largely driven by a 38% yoy increase in US generics, 35% growth in Russia and 28% growth in the PSAI segment. US growth was led by limitedcompetition products such as ziprasidone, tacrolimus and fondaparinux, and market-share gains in metoprolol, atorvastatin and montelukast. Higher growth in Russia stemmed from seasonal offtake across the product portfolio. At the same time, CIS business grew 18.5% to Rs 660 mn.

Backed by the favorable currency movements and launch of new APIs due to patent expiries during the year, growth in the PSAI segment was a healthy at 25.7% on a YoY basis. However, gross margins declined by 840 bps sequentially to 27.4% several high-value APIs did not receive approval during Q3FY13. We believe that 75% of the PSAI segment's revenues come from APIs, which is not a consistent business and there is lumpiness QoQ. Over the same period, SG&A spend escalated on account of US $1 mn led by GDUFA fee, spate of launches (especially from the bio-generics side) in emerging markets, and spend towards OTC portfolio in the US and Russia.

Despite current performance, rich product pipeline (63 ANDA's pending approval), 7 FTF opportunities and 33 Para IVs would drive Dr Reddy's revenue in the long term. However, considering the high base of FY13, we expect DRL performance in FY14 to remain muted and restricted to single digit growth. Currently, the stock is trading at 17.2x and 15.2x of its FY14E and FY15E consensus earnings. Factoring the weak outlook for FY14, slower pace of ANDA's filings, we recommend a HOLD on the stock," says Ventura Securities research report.

Institutional holding more than 40% in Indian cos

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

To read the full report click here

Ads by Google

Buy, Hold, Sell ? Hear it first on M3
Hold Dr Reddys Laboratories: Ventura Securities

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login